An artificial intelligence-powered test as a digital cognitive biomarker for monitoring individuals with moderate cognitive impairment (MCI) and Alzheimer’s Disease has been validated in a recently published peer-reviewed article.
The Integrated Cognitive Assessment (ICA) is a dementia early detection test created by Cognetivity Neurosciences, a digital health company based in the United Kingdom.
A new study, published in Frontiers in Psychiatry, investigates the use of AI for these particular illnesses.
- Does This Mean We Stopped Being Animal and Started Being Human Due to ‘Copy Paste’ Errors?
- The One Lifestyle Choice That Could Reduce Your Heart Disease Risk By More Than 22%
- Aging: This Is What Happens Inside Your Body Right After Exercise
- Immune-Boosting Drink that Mimics Fasting to Reduce Fat – Scientists ‘Were Surprised’ By New Findings
- Gun Violence in America: What They Don’t Talk About at the Debate
The technology employs artificial intelligence and machine learning methods to help in the detection of early indications of impairment by assessing the functioning of vast regions of the brain in order to aid in the diagnosis of dementia. It has received regulatory clearance for clinical usage in the United Kingdom and Europe, with clinical approval in North America expected in the near future.
The study confirms the ICA’s sensitivity to early dementia symptoms and confirms that it is culture-static and bias-free, allowing for fast, global implementation, including risk-based screening in primary care.
The study discovered that the ICA performs consistently across various foreign populations. What’s crucial here is that the findings may be generalised across them without the requirement for additional settings to gather population-specific normative data.
Most conventional cognitive tests have the drawback of requiring the gathering of language and culture-specific data in new global locations before being scaled up.
The ICA’s appropriateness was determined via a survey of more than 200 research participants from various cultures. There were no disparities in language, culture, or education when the data was compared to other techniques. The AI was able to make these assessments remotely.
The ICA is intended to identify those who require therapy as well as those who are most likely to benefit from a certain kind of pharmacological intervention in the near future.
- Does This Mean We Stopped Being Animal and Started Being Human Due to ‘Copy Paste’ Errors?
- The One Lifestyle Choice That Could Reduce Your Heart Disease Risk By More Than 22%
- Aging: This Is What Happens Inside Your Body Right After Exercise
- Immune-Boosting Drink that Mimics Fasting to Reduce Fat – Scientists ‘Were Surprised’ By New Findings
- Gun Violence in America: What They Don’t Talk About at the Debate
“The diagnostic accuracy of the ICA and its novel use of explainable AI, combined with the power to generalize across other languages and cultures, make it uniquely suitable for cognitive screening across large and diverse populations,” says lead researcher geriatric psychiatrist Professor Dag Aarsland.
Image Credit: Getty